Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results.

Peet, Malcolm

Peet, Malcolm.

Affiliation

Peet M; Swallownest Court Hospital, Aughton Road, Sheffield S26 4TH, UK. malcolmpeet@yahoo.com

Prostaglandins Leukot Essent Fatty Acids ; 69(6): 477-85, 2003 Dec.

Article in En | MEDLINE | ID: mdl-14623502

Subject(s)

Antipsychotic Agents/therapeutic use; Depressive Disorder/drug therapy; Eicosapentaenoic Acid/therapeutic use; Schizophrenia/drug therapy; Antipsychotic Agents/metabolism; Depressive Disorder/metabolism; Double-Blind Method; Eicosapentaenoic Acid/metabolism; Fatty Acids, Omega-3/metabolism; Fatty Acids, Omega-3/therapeutic use; Humans; Phospholipids/metabolism; Placebos; Schizophrenia/etiology; Schizophrenia/metabolism

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Antipsychotic Agents / Eicosapentaenoic Acid / Depressive Disorder Type of study: Clinical_trials / Etiology_studies Limits: Humans Language: En Journal: Prostaglandins Leukot Essent Fatty Acids Journal subject: ENDOCRINOLOGIA Year: 2003 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links